Hannah M Lee1, Joseph Ahn2, W Ray Kim3, Joseph K Lim4, Mindie Nguyen3, Calvin Q Pan5, Donghee Kim3, Ajitha Mannalithara3, Helen Te6, Huy Trinh7, Danny Chu8, Tram Tran9, Jocelyn Woog10, Anna S Lok11. 1. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Medical Center, 1200 E. Broad St., 14th Floor, P.O. Box 980341, Richmond, VA, 23298, USA. hannah.lee@vcuhealth.org. 2. Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, OR, USA. 3. Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA. 4. Yale University, New Haven, CT, USA. 5. Division of Gastroenterology and Hepatology, NYU Langone Health, NYU School of Medicine, New York, USA. 6. Digestive Disease Center, University of Chicago, Chicago, IL, USA. 7. San Jose Gastroenterology, San Jose, CA, USA. 8. Albert Einstein College of Medicine, New York, NY, USA. 9. Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA. 10. Asian Health Foundation, Rochester, MN, USA. 11. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND AND AIMS: The management of chronic hepatitis B patients is not well characterized in real-world practice. We compared baseline characteristics of CHB patients on entecavir, the frequency of on-treatment monitoring, and the effectiveness of ETV treatment between academic and community practices. METHODS: Treatment-naïve CHB patients ≥18 years old, treated with ETV for ≥12 months from 2005 to 2013, in 26 community and academic practices throughout the USA were retrospectively evaluated. RESULTS: Of 841 patients enrolled, 658 (65% male, 83% Asian, median age 47, 9% with cirrhosis) met inclusion criteria. Half of the patients (52%) were from community practices. A lower percentage of patients in community practices had cirrhosis or liver cancer (5 vs. 14%). Community practices more often treated patients with baseline ALT < 2 × ULN. Over a median follow-up of 4 years, community practices were more likely to discontinue ETV with less frequent laboratory monitoring compared to academic practices. The 5-year cumulative probability of ALT normalization was greater among patients treated in community practices (70 vs. 50%, p < 0.001), but the 5-year cumulative probability of undetectable HBV DNA was lower (45 vs. 70%, p < 0.001) than those treated in academic practices. CONCLUSION: Academic practices saw CHB patients with more advanced liver disease, more often followed AASLD guidelines, and monitored patients on ETV treatment more frequently than community practices. While patients in community practices were less likely to achieve undetectable HBV DNA and more likely to achieve ALT normalization, the rates of HBeAg loss and seroconversion as well as HBsAg loss were similar.
BACKGROUND AND AIMS: The management of chronic hepatitis Bpatients is not well characterized in real-world practice. We compared baseline characteristics of CHB patients on entecavir, the frequency of on-treatment monitoring, and the effectiveness of ETV treatment between academic and community practices. METHODS: Treatment-naïve CHB patients ≥18 years old, treated with ETV for ≥12 months from 2005 to 2013, in 26 community and academic practices throughout the USA were retrospectively evaluated. RESULTS: Of 841 patients enrolled, 658 (65% male, 83% Asian, median age 47, 9% with cirrhosis) met inclusion criteria. Half of the patients (52%) were from community practices. A lower percentage of patients in community practices had cirrhosis or liver cancer (5 vs. 14%). Community practices more often treated patients with baseline ALT < 2 × ULN. Over a median follow-up of 4 years, community practices were more likely to discontinue ETV with less frequent laboratory monitoring compared to academic practices. The 5-year cumulative probability of ALT normalization was greater among patients treated in community practices (70 vs. 50%, p < 0.001), but the 5-year cumulative probability of undetectable HBV DNA was lower (45 vs. 70%, p < 0.001) than those treated in academic practices. CONCLUSION: Academic practices saw CHB patients with more advanced liver disease, more often followed AASLD guidelines, and monitored patients on ETV treatment more frequently than community practices. While patients in community practices were less likely to achieve undetectable HBV DNA and more likely to achieve ALT normalization, the rates of HBeAg loss and seroconversion as well as HBsAg loss were similar.
Authors: J Ahn; H M Lee; J K Lim; C Q Pan; M H Nguyen; W Ray Kim; A Mannalithara; H Trinh; D Chu; T Tran; A Min; S Do; H Te; K R Reddy; A S Lok Journal: Aliment Pharmacol Ther Date: 2015-10-28 Impact factor: 8.171
Authors: Jeong Won Jang; Jong Young Choi; Young Seok Kim; Hyun Young Woo; Sung Kyu Choi; Chang Hyeong Lee; Tae Yeob Kim; Joo Hyun Sohn; Won Young Tak; Kwang-Hyub Han Journal: Hepatology Date: 2015-03-18 Impact factor: 17.425
Authors: Sue Zhang; Jessica T Ristau; Huy N Trinh; Ruel T Garcia; Huy A Nguyen; Mindie H Nguyen Journal: Dig Dis Sci Date: 2012-03-31 Impact factor: 3.199
Authors: Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias Journal: Clin Gastroenterol Hepatol Date: 2008-08-23 Impact factor: 11.382
Authors: Emmet B Keeffe; Douglas T Dieterich; Steve-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias; Teresa L Wright Journal: Clin Gastroenterol Hepatol Date: 2004-02 Impact factor: 11.382
Authors: Joi Lee; Chi Chu; David Guzman; Valy Fontil; Alexandra Velasquez; Neil R Powe; Delphine S Tuot Journal: Am J Nephrol Date: 2019-06-05 Impact factor: 3.754
Authors: Calvin Q Pan; Nezam H Afdhal; Victor Ankoma-Sey; Ho Bae; Michael P Curry; Douglas Dieterich; Lynn Frazier; Andrew Frick; Hie-Won Hann; W Ray Kim; Paul Kwo; Scott Milligan; Myron J Tong; K Rajender Reddy Journal: Hepatol Commun Date: 2022-04-21